HTG to Sponsor Keynote Presentation Featuring Customer Use of its HTG EdgeSeq Technology in Clinical Trials
HTG Molecular Diagnostics (Nasdaq: HTGM) will sponsor a keynote presentation at the 7th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference in San Diego on June 16, 2022, at 9:05 AM PT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
HTG Molecular Diagnostics (Nasdaq: HTGM) will sponsor a keynote presentation at the 7th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference in San Diego on June 16, 2022, at 9:05 AM PT. The presentation, titled “Implementing Biomarker Strategy in Clinical Trials,” will feature Chetan Deshpande from Pfizer, who will discuss how HTG’s EdgeSeq technology addresses clinical trial challenges. HTG focuses on advancing precision medicine through innovative transcriptome-wide profiling to enhance diagnostics and therapeutic strategies.
Positive
- Sponsoring a keynote at a major conference demonstrates HTG's engagement in the life sciences sector.
- Keynote presentation by a Pfizer representative highlights HTG's role in addressing clinical trial challenges.
- HTG's proprietary EdgeSeq technology is being utilized by industry leaders like Pfizer.
Negative
- None.
Details
News Market Reaction – HTGM
The recorded move for HTGM in the trading session of this news was +12.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TUCSON, Ariz., June 08, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that it will be sponsoring a keynote presentation at the 7th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference in San Diego, CA, titled “Implementing Biomarker Strategy in Clinical Trials” on June 16th at 9:05 AM PT.
This presentation will feature Chetan Deshpande, Director, Biomarker Clinical Assay Lead, Global Product Development at Pfizer. Mr. Deshpande will discuss the challenges that are generally faced in clinical trials and how Pfizer has leveraged HTG’s proprietary gene expression profiling HTG EdgeSeq technology in multiple clinical trials to overcome these challenges.
Details of the Keynote Presentation are below:
| Date: | Thursday, June 16th |
| Time: | 9:05 AM PT |
| Access: | Conference Website |
About HTG:
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.
HTG Investor Contact:
Ashley Robinson
LifeSci Advisors
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.